A Study of Ibandronate (Bondronat) in Participants With Metastatic Bone Disease

Pain; Bone Neoplasms; Neoplasm Metastasis Clinical Trial

Official title:
An Open Label Study of the Efficacy, Safety, and Pharmacoeconomics of Oral Ibandronate (Bondronat 50 mg) in Treatment of Metastatic Bone Disease

Status Completed

Clinical Trial Summary

This study will evaluate the efficacy, safety, and effect on quality of life of oral ibandronate (Bondronat) in participants with breast cancer and metastatic bone disease. The anticipated time on study treatment is 25 weeks, and the target sample size is 50 individuals.

Clinical Trial Description

n/a

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Bone Diseases
Bone Neoplasms
Neoplasm Metastasis
Pain; Bone Neoplasms; Neoplasm Metastasis

Clinical Trial Details

NCT number	NCT02564107
Study type	Interventional
Source	Hoffmann-La Roche
Contact
Status	Completed
Phase	Phase 4
Start date	November 2004
Completion date	April 2006

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02553707` - A Study to Assess the Short Term Efficacy of Intravenous Ibandronate (Bondronat) in Participants With Metastatic Bone Pain Due to Breast Cancer	Phase 4
Completed	`NCT00502736` - A Study of Loading Doses of Intravenous Bondronat (Ibandronate) in Patients With Breast Cancer and Malignant Bone Disease.	Phase 2
Completed	`NCT02561039` - A Study of Ibandronate (Bondronat) in Participants With Malignant Bone Disease	Phase 3